All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
The U.S. Food and Drug administration (FDA) have agreed to start a submission process for a Biologics License Application (BLA) for inolimomab for the treatment of adult patients with Grade 2–4 steroid-refractory acute graft-versus-host disease (aGvHD).1 This move comes following the demonstration of the significant and durable efficacy of inolimomab in a randomized multicenter phase III study (INO-0107—EUDRACT 2007-005009-24). While this trial did not meet its primary endpoint (overall survival after 1 year), patients treated with inolimomab showed a more favorable outcome after longer term follow-up compared to those who had received antithymocyte globulin.2
The BLA will be reviewed under the FDA’s Real-Time Oncology Review pilot program, which aims to make the reviewing process more efficient.
Inolimomab is a monoclonal antibody that targets interleukin-2 (IL-2) and is involved in the development and multiplication of certain white blood cells, including T cells responsible for aGvHD. Inolimomab blocks IL-2 from binding to CD25 by specifically linking to and blocking the receptor on the surface of the T cell, preventing their proliferation.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content